Pfizer Corporation

Pharmacia Corporation

Other

Warner-lambert Company

John Isidro Trujillo

Atli Thorarensen

Wei Huang

Brian Stephen Gerstenberger

Jean-Baptiste Telliez

Rayomand Jal Unwalla

William L Neumann

Melvin L Rueppel

Horng-Chih Huang

Michael S South

John Joseph Parlow

Darin E Jones

Agustin Casimiro-Garcia

Scott A Long

Brenda Case

Michael J Hayes

Matthew Frank Brown

Mark Edward Flanagan

Adam Matthew Gilbert

Ariamala Gopalsamy

Eddine Saiah

Matthew Merrill Hayward

Li Huang Xing

Ivan Viktorovich Efremov

Ye Che

Zhao-Kui Wan

Liying Zhang

Andrew Fensome

Betsy Susan Pierce

David B Reitz

Jotham Wadsworth Coe

Bruce C Hamper

Mark E Schnute

Justin Ian Montgomery

Steven Ronald Turner

Daniel Wei-Shung Kung

Andrew Christopher Flick

Ralph Pelton Robinson, Jr

Jonathan David Langille

Richard John Lindmark

Philippe Marcel Nuhant

Ching-Cheng Wang

Qingping Zeng

Kirk Lang Olson

Matthew William Mahoney

Rhonda Wood

Tanisha D Blake

James R Kiefer, Jr

Vincent Michael Lombardo

Joseph B Moon

Bradley E Neal

James John Mousseau

Matthew J Pelc

Barbara A Schweitzer

Daniel Copley Schmitt

Huixian Wu

Gary W Franklin

Carrie Kusturin

Alan E Moormann

Mihaly V Toth

Rajesh Devraj

Robert Owen Hughes

Donald J Rogier

Ronald Keith Webber

Jeffrey A Scholten

Jeffery S Snyder

Danny J Garland

Steve R Turner

Tom Dice

Rick Fenton

Joseph Walter Strohbach

Jennifer Elizabeth Davoren

Scott William Bagley

Frank Eldridge Lovering

Sidney Xi Liang

Mihir D Parikh

Rajiah Aldrin Denny

Ricky L Fenton

Xiayun Cheng

Thomas A Dice

Rajesh Venkateswaran Devraj

Donald Joseph Rogier

Steve Ronald Turner

Donald Joseph Rogier Jr

The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.

N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors

The present invention provides a method for treating alopecia using certain pharmaceutically active pyrrolo[2,3-d]pyrimidinyl acrylamides having the structure: or a pharmaceutically acceptable salt thereof, as set forth in the Description.

Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides

The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein Rto Rare as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.

Benzimidazole derivative compounds and uses thereof

A compound compound having the structure: or a pharmaceutically acceptable salt thereof, wherein X is N or CR, where R is hydrogen, deuterium, C-Calkyl, C-Calkoxy, C-Ccycloalkyl, aryl, heteroaryl, aryl(C-Calkyl), CN, amino, alkylamino, dialkylamino, CF, or hydroxyl; A is selected from the group consisting of a bond, C&#x2550;O, &#x2014;SO&#x2014;, &#x2014;(C&#x2550;O)NR&#x2014;, and &#x2014;(CRR)&#x2014;, where Ris H or C-Calkyl, and Rand Rare independently hydrogen, deuterium, C-Calkyl, C-Ccycloalkyl, aryl, aryl(C-Calkyl), heteroaryl, (C-Calkyl)heteroaryl, etc.; A' is selected from the group consisting of a bond, C&#x2550;O, &#x2014;SO&#x2014;, &#x2014;(C&#x2550;O)NR&#x2032;, &#x2014;NR&#x2032;(C&#x2550;O)&#x2014;, and &#x2014;(CR&#x2032;R&#x2032;)&#x2014;, where R&#x2032; is H or C-Calkyl, and R&#x2032; and R&#x2032; are independently hydrogen, deuterium, C-Calkyl, C-Ccycloalkyl, aryl, aryl(C-Calkyl), heteroaryl, (C-Calkyl)heteroaryl, heteroaryl(C-Calkyl), and heterocyclic(C-Calkyl); Z is &#x2014;(CH)&#x2014; or a bond, where one or more methylene units are optionally substituted by one or more C-Calkyl, CN, OH, methoxy, or halo, and where said alkyl may be substituted by one or more fluorine atoms; Rand R&#x2032; are independently selected from the group consisting of hydrogen, deuterium, C-Calkyl, C-Ccycloalkyl, aryl, heteroaryl, aryl(C-Calkyl), CN, etc., wherein said alkyl, aryl, cycloalkyl, heterocyclic, or heteroaryl is further optionally substituted with one or more substituents selected from the group consisting of C-Calkyl, halo, CN, C-Calkylamino, C-Ccycloalkyl, etc.; Ris selected from the group consisting of hydrogen, deuterium, C-Calkyl, C-Ccycloalkyl, halo, and cyano, where said alkyl may be substituted by one or more fluorine atoms; Ris selected from the group consisting of hydrogen, deuterium, and amino; Ris monocyclic or bicyclic aryl or monocyclic or bicyclic heteroaryl wherein said aryl or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of C-Calkyl, heterocycloalkyl, halo, C-Ccycloalkyl, etc., where said alkyl, cycloalkyl, alkoxy, or heterocycloalkyl may be substituted by one or more C-Calkyl, halo, CN, OH, alkoxy, amino, &#x2014;COH, &#x2014;(CO)NH, &#x2014;(CO)NH(C-Calkyl), or &#x2014;(CO)N(C-Calkyl), and where said alkyl may be further substituted by one or more fluorine atoms; Ris independently selected from the group consisting of hydrogen, C-Calkyl, C-Calkoxy, and hydroxyl; h is 1, 2 or 3; j and k are independently 0, 1, 2, or 3; m and n are independently 0, 1 or 2; and, q is 0, 1 or 2. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations with other therapeutic agents.

Aminopyrimidinyl compounds

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylam ides and analogues thereof, having the structure: or a pharmaceutically acceptable salt thereof, as set forth in the Description. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

A compound having the structure: or an acceptable salt thereof, wherein X is N or CR, where R is hydrogen, alkyl, etc.; A is selected from the group consisting of a bond, C&#x2550;O, &#x2014;SO&#x2014;, etc.; A' is selected from the group consisting of a bond, C&#x2550;O, etc.; Z is &#x2014;(CH)&#x2014; or a bond, etc.; Rand Rare independently selected from the group consisting of hydrogen, alkyl, etc.; Ris selected from hydrogen, alkyl, etc.; Ris selected from the group consisting of hydrogen, and amino; Ris monocyclic or bicyclic, etc.; Ris independently selected from hydrogen, alkyl, etc.; h, j, k, m, n and q are integers as defined in the specification. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations with other therapeutic agents.

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, and pyrrolo[2,3-b]pyridinyl acrylamides, epoxides, and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

Pyrrolo[2,3-D]pyrimidinyl, pyrrolo[2,3-B]pyrazinyl, pyrrolo[2,3-B]pyridinyl acrylamides and epoxides thereof

A shelf system has a shelf component and a support frame component configured to removably support the shelf component in a cantilever fashion in an assembled state of the shelf system. The shelf component has a top surface, a bottom surface, a front end, a rear end, opposite sides between the front and rear ends, and a longitudinal groove formed in the bottom surface between the opposite sides. The support frame component is formed of a base panel having a front side, a rear side, a top end, a bottom end and opposite lateral sides between the top and bottom ends. A pair of support members extend from the front side of the support frame component for supporting a cross member. The longitudinal groove of the shelf component is configured to engage the cross member of the support frame component in the assembled state of the shelf system.

Shelf system

A compound having the structure: or an acceptable salt thereof, wherein X is N or CR, where R is hydrogen, alkyl, etc.; A is selected from the group consisting of a bond, C&#x2550;O, &#x2014;SO&#x2014;, etc.; A' is selected from the group consisting of a bond, C&#x2550;O, etc.; Z is &#x2014;(CH)&#x2014; or a bond, etc.; Rand R&#x2032; are independently selected from the group consisting of hydrogen, alkyl, etc.; Ris selected from hydrogen, alkyl, etc.; Ris selected from the group consisting of hydrogen, and amino; Ris monocyclic or bicyclic, etc.; Ris independently selected from hydrogen, alkyl, etc.; h, j, k, m, n and q are integers as defined in the specification. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations with other therapeutic agents.

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof, having the structure: or a pharmaceutically acceptable salt or solvate thereof, or an enantiomer or diastereomer thereof, as set forth in the Description. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

There is provided a compound of Formula I(a) or I(b): or a pharmaceutically acceptable salt thereof, wherein the various substitutents are defined herein.

3-aminocyclopentanecarboxamides as chemokine receptor agonists

There is provided a compound of Formula I(a) or I(b) or a pharmaceutically acceptable salt thereof, wherein the various substituents are defined herein.

Growing community of inventors

Ledyard, CT, United States of America

John Isidro Trujillo